312 related articles for article (PubMed ID: 36551652)
1. Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies.
Guillaume Z; Auvray M; Vano Y; Oudard S; Helley D; Mauge L
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551652
[TBL] [Abstract][Full Text] [Related]
2. Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway.
Wang N; Wang R; Tang J; Gao J; Fang Z; Zhang M; Shen X; Lu L; Chen Y
Contrast Media Mol Imaging; 2022; 2022():5602011. PubMed ID: 36176934
[TBL] [Abstract][Full Text] [Related]
3. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
4. CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC.
Biswas S; Charlesworth PJ; Turner GD; Leek R; Thamboo PT; Campo L; Turley H; Dildey P; Protheroe A; Cranston D; Gatter KC; Pezzella F; Harris AL
Carcinogenesis; 2012 Sep; 33(9):1717-25. PubMed ID: 22777959
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
6. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
7. Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Pircher A; Wolf D; Heidenreich A; Hilbe W; Pichler R; Heidegger I
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088109
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Sawhney R; Kabbinavar F
Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
[TBL] [Abstract][Full Text] [Related]
9. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
10. The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies.
Ileiwat ZE; Tabish TA; Zinovkin DA; Yuzugulen J; Arghiani N; Pranjol MZI
Front Immunol; 2022; 13():976677. PubMed ID: 36045675
[TBL] [Abstract][Full Text] [Related]
11. CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma.
Liu S; Xu C; Zhang K; Han D; Yang F; Li Y; Zhao X; Ma S; Li H; Lu S; Lu T; Zhang J; Qin W; Wen W; Yang B
Ann Transl Med; 2021 Dec; 9(23):1741. PubMed ID: 35071435
[TBL] [Abstract][Full Text] [Related]
12. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
14. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
15. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
16. Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
Zhang T; Zhu J; George DJ; Nixon AB
Urol Oncol; 2016 Nov; 34(11):510-518. PubMed ID: 27498927
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.
Rodriguez-Vida A; Strijbos M; Hutson T
ESMO Open; 2016; 1(3):e000013. PubMed ID: 27843601
[TBL] [Abstract][Full Text] [Related]
18. Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation.
Vlachostergios PJ
J Kidney Cancer VHL; 2020; 7(1):7-11. PubMed ID: 32983840
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
20. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
